Funding for this research was provided by:
F. Hoffmann-La Roche (Institutional funding to Aarhus University)
Text and Data Mining valid from 2018-10-16
Received: 5 October 2017
Accepted: 27 September 2018
First Online: 16 October 2018
Ethics approval and consent to participate
: The study received a required approval by the Danish Data Protection Agency [record numbers 2015-57-0002 (previously 2015-41-3838) and 2013-41-1754]. The study protocol is registered as Post-Authorisation Safety Study with the ENCePP Register of Studies, with study number EUPAS12875 (Roche identifier: BV29684). There is no requirement by Danish law to obtain informed consent or an approval by an Institutional Review Board for a registry-based study.
: Not applicable.
: BM, BC and AK are full-time employees and hold stock and/or stock options in Roche, the manufacturer of oseltamivir. VE, NRK, and HTS are salaried employees of Aarhus University/Aarhus University Hospital. HTS is supported by the Program for Clinical Research Infrastructure (PROCRIN), established by the Lundbeck Foundation and the Novo Nordisk Foundation and administered by the Danish Regions. This study was funded by F. Hoffmann-La Roche Ltd. through a research agreement to and administered by Aarhus University.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.